ArticleFrontiers in oncology2026
Development of an early diagnostic model for gastric cancer combining serum cytokine profiles with conventional tumor markers: a case-control study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early detection of gastric cancer (GC) remains challenging, and conventional serum tumor markers show limited sensitivity for precancerous gastric lesions. Inflammatory cytokines change during tumorigenesis and may provide complementary information for noninvasive screening. We evaluated whether serum cytokine profiling combined with routine tumor markers could improve discrimination across the spectrum from healthy mucosa to precancerous lesions and early GC. Methods: In this single-center, cross-sectional case-control study, 165 participants were enrolled: 60 patients with GC (including 15 high-grade intraepithelial neoplasia [HGIN]/carcinoma Results: Compared with HC, GC cases exhibited higher IL-6, IL-8, IL-10, IL-16, IL-17, IL-21, and TNF-α, and lower IL-1ra and IL-7. GPL cases showed increased IL-16 and IL-17 and decreased IL-7,IL-16 correlated moderately with IL-10(r=0.62), suggesting coordinated inflammatory-immunoregulatory signaling. As individual markers, IL-16 yielded an AUC of 0.91 for GC versus HC, IL-7 yielded an AUC of 0.76 for GC versus GPL, and IL-16 and IL-17 showed value for detecting GPL (AUCs 0.74 and 0.73, respectively). Multimarker combinations improved discrimination: IL-6+IL-7+IL-16+CEA reached an AUC of 0.93 for GC versus GPL; IL-6+IL-16+IL-17 reached an AUC of 0.92 for GPL versus HC; and an integrated model discriminating GC from HC achieved an AUC of 0.97. Bootstrap internal validation showed optimism-corrected AUCs of 0.902, 0.889, and 0.927 for these three combined models, respectively SHAP-based ranking indicated that IL-16, IL-6, CEA, and IL-7 were the main contributors to the 12-analyte model, whereas IL-21 had relatively low marginal contribution. Conclusions: Serum inflammatory cytokine patterns change early during gastric carcinogenesis. Combining cytokine profiles with conventional tumor markers substantially enhances noninvasive discrimination of precancerous lesions and early GC. However, these findings should be interpreted as exploratory and require multicenter and longitudinal validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.